Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

3 Months Ended

Oct. 31, 2018

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended October 31, 2018	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues		14,297			6,963			—			—			21,260

Operating costs and expenses:
Cost of revenues		10,968			3,271			—			—			14,239
Research and development		—			507		$	221			—			728
Selling, general and administrative		6,060			2,924			—		$	1,986			10,970
Legal fee expense		36			7			—			1,258			1,301
Total operating costs and expenses		17,064			6,709			221			3,244			27,238

Operating income (loss)		(2,767	)		254			(221	)		(3,244	)		(5,978	)

Other income (expense):
Interest		(18	)		16			—			276			274
Other		40			4			—			3			47
Foreign exchange loss		—			(324	)		—			—			(324	)
Loss before income taxes	$	(2,745	)	$	(50	)	$	(221	)	$	(2,965	)	$	(5,981	)

Depreciation and amortization included above	$	403		$	342		$	—		$	21		$	766

Share-based compensation included in above:
Selling, general and administrative		38		$	24			—		$	173			235
Total	$	38		$	24		$	—		$	173		$	235

Capital expenditures	$	354		$	52		$	—		$	—		$	406

Three months ended October 31, 2017	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues		19,534			7,342			—			—			26,876

Operating costs and expenses:
Cost of product revenues		12,042			3,389			—			—			15,431
Research and development		—			523		$	224			—			747
Selling, general and administrative		6,095			2,628			—		$	2,182			10,905
Legal fee expense		13			3			—			415			431
Total operating costs and expenses		18,150			6,543			224			2,597			27,514

Operating income (loss)		1,384			799			(224	)		(2,597	)		(638	)

Other income (expense):
Interest		(25	)		12			—			170			157
Other		14			7			—			15			36
Foreign exchange gain		—			(195	)		—			—			(195	)
Income (loss) before income taxes	$	1,373		$	623		$	(224	)	$	(2,412	)	$	(640	)

Depreciation and amortization included above	$	404		$	326		$	—		$	19		$	749

Share-based compensation included in above:
Selling, general and administrative		32		$	23			—		$	150			205
Total	$	32		$	23		$	—		$	150		$	205

Capital expenditures	$	418		$	43		$	—		$	—		$	461